This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

trusted source


Researchers uncover mechanisms of brexanolone and the role of inflammation in post-partum depression

Researchers Uncover Mechanisms of Brexanolone and the Role of Inflammation in Post-partum Depression
Brexanolone infusion alters multiple steroid levels in PPD patient serum. Serum was collected ∼1 h pre- and 6 h post-brexanolone (Brex) infusion (60 h) and simultaneously analyzed for the levels of allopregnanolone, pregnanolone (3α,5β-THP), allotetrahydrodeoxycorticosterone (3α,5α-THDOC), pregnenolone, 3α,5α-androsterone and 3α,5α-androstan-diol by gas chromatography-mass spectrometry (GCMS). Since the data values did not represent normal (Gaussian) distribution using the Kolmogorov–Smirnov normality test, Multiple Wilcoxon matched-pairs signed rank tests with Bonferroni-Dunn correction (MLT Wilcoxon BFD) for the multiple comparisons were applied to determine the effects of brexanolone infusion on the levels of the neurosteroids. The median values of differences in picograms/milliliter (pg/ml), % confidence intervals (CI) of differences, sum of signed ranks (W), p and adjusted p values were examined. Brexanolone infusion increased the levels of allopregnanolone (Npairs = 16) and 3α, 5α-THDOC (Npairs = 18), while decreasing 3α,5α-androsterone ( Npairs = 16) and 3α,5α-androstan-diol ( (Npairs = 18). The changes in the levels of 3α,5β-THP (Npairs = 15) and pregnenolone (Npairs = 18) after brexanolone infusion were not statistically significant. The W values, p and adjusted p values are presented in the figure. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001 [MLT Wilcoxon BFD]. Credit: eBioMedicine (2023). DOI: 10.1016/j.ebiom.2023.104473

Post-partum depression (PPD) develops after childbirth and affects both the mother's and the infant's health by preventing healthy bonding. Women with PPD experience intense anxiety, feelings of depression, sleeplessness, inability to care for their child, and risk for suicide.

Brexanolone, an IV infusion comprised of a derivative of progesterone, was approved by the U.S. Food and Drug Administration for the treatment of PPD in 2019. The fast-acting medication significantly reduces symptoms and provides effects for up to 90 days. However, exactly how the drug provides these therapeutic effects has remained a mystery—until now.

A research team led by A. Leslie Morrow, Ph.D., the John Andrews Distinguished Professor of Psychiatry and Pharmacology in the UNC School of Medicine, has found that brexanolone works within the body by inhibiting the key systemic inflammatory pathways that are associated with depression. The new finding is monumental in that it suggests that PPD is likely caused, at least in part, by inflammation.

"We found that brexanolone inhibited the responsible for the production of cytokines and chemokines—the markers of inflammation," said Morrow. Toll-like receptors are like gatekeepers on the surface of cells, recognizing molecules and then initiating a cell's inflammatory response. "Our results provide the first human data showing that blockade of specific inflammatory pathways is likely involved, at least in women who were unresponsive to other medications."

Their results were published in eBioMedicine.

According to recent studies, one in eight women experience post-partum , and the prevalence of depression diagnoses at delivery is rising. The CDC reports that rates in 2015 were seven times higher than they were in 2000.

However, scientists are still unsure of what causes PPD to develop in the brain.

One potential cause of PPD could be deficiency in GABAergic transmission, which calms the brain via a neurotransmitter known as GABA. GABA, or y-Aminobutyric acid, is found in our central nervous systems and instructs our bodies to stop, or inhibit, the activity of neurons. Additionally, PPD could also be caused by deficits in our normal responses to stress.

But recent data and this new study suggest that inflammation may be contributing to the syndrome.

Much like other types of depression, PPD is typically treated with SSRIs, but sometimes patients don't improve with to conventional therapy. Now, doctors are able to prescribe brexanolone in such circumstances. Brexanolone was initially approved in 2019, but the mechanism underlying its antidepressant action was unclear at the time.

The research suggests that the of brexanolone are likely brought on by its ability to inhibit toll-like receptor pathways and reduce inflammatory markers. The same inflammatory markers have been shown to be up-regulated in PPD, which means that inflammation may be at least partially responsible for the condition.

By the same reasoning, brexanolone or other may also be effective for treating other types of depression that elevate inflammatory markers. The team hopes that their new findings may lead to more cost-effective treatments that can block the same inflammatory pathways that were identified in the study.

More information: Irina Balan et al, Brexanolone therapeutics in post-partum depression involves inhibition of systemic inflammatory pathways, eBioMedicine (2023). DOI: 10.1016/j.ebiom.2023.104473

Journal information: EBioMedicine

Citation: Researchers uncover mechanisms of brexanolone and the role of inflammation in post-partum depression (2023, February 20) retrieved 2 June 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Brexanolone tolerated in super-refractory status epilepticus


Feedback to editors